The Kansas City Cardiomyopathy Questionnaire in Relation to New York Heart Association Class
Authors:
Open Access
- 28 September 2024
- journal article
- research article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 31 (2) , 481-484
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
This publication has 8 references indexed in Scilit:
- Impact of Patient-Reported Outcome Measurement in Heart Failure Clinic on Clinician Health Status Assessment and Patient Experience: A Substudy of the PRO-HF TrialCirculation: Heart Failure, 2023
- Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic CardiomyopathyJACC: Heart Failure, 2022
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2021
- 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic CardiomyopathyCirculation, 2020
- Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical CareJACC, 2020
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2020
- Comparison of Patient Self-reported Health Status With Clinician-Assigned New York Heart Association ClassificationJAMA Network Open, 2020
- Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac diseaseHeart & Lung, 2002